

**EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED DECEMBER 31, 2018**

**(Rs. in Million, except per equity share data)**

Particulars	3 months ended 31.12.2018	9 Months ended 31.12.2018	3 months ended 31.12.2017
	(Unaudited)	(Unaudited)	(Unaudited)
I Total income from operations	15,408	39,856	10,579
II Net profit before share of profit of joint venture and associates, tax, exceptional items and non-controlling interest	2,710	7,239	1435
III Net profit before tax and non-controlling interest	2,893	9,306	1,497
IV Net profit after tax and non-controlling interest	2,172	6,916	919
V Total comprehensive income for the period attributable to shareholders [comprising profit for the period (after tax) and other comprehensive income (after tax)]	2,213	6,131	1,116
VI Paid-up equity share capital [Face value of Rs. 5 each]	3,000	3,000	3,000
VII Earnings per share [of Rs. 5 each]	(not annualised)	(not annualised)	(not annualised)
(a) Basic	3.67	11.69	1.56
(b) Diluted	3.64	11.61	1.55

**1. Key standalone financial information**

**(Rs. in Million)**

Particulars	3 months ended 31.12.2018	9 Months ended 31.12.2018	3 months ended 31.12.2017
	(Unaudited)	(Unaudited)	(Unaudited)
Total income from operations	7,397	21,208	5,921
Profit before tax	820	4,778	600
Profit after tax	727	4,222	437

- The unaudited standalone and consolidated financial results for the quarter and nine month ended December 31, 2018 in respect of Biocon Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on January 24, 2019. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified.
- These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The adoption of Ind AS 115: Revenues from Contracts with Customers and the consequential impact on change in some of the licensing arrangements did not have a material impact on the Revenue from Operations and results for the quarter and nine month ended December 31, 2018. For further details, please refer to the full format of Unaudited Financial Results.
- The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Stock Exchange websites, [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and on the Company's website [www.biocon.com](http://www.biocon.com).